TN2015000106A1 - 5-phenoxy-3h-pyrimidin-4-one derivatives and their use as hiv reverse transcriptase inhibitors - Google Patents

5-phenoxy-3h-pyrimidin-4-one derivatives and their use as hiv reverse transcriptase inhibitors

Info

Publication number: TN2015000106A1
Authority: TN; Tunisia
Prior art keywords: reverse transcriptase; hiv reverse; transcriptase inhibitors; pyrimidin; phenoxy
Prior art date: 2012-10-08

Application number

TNP2015000106A

Other languages

English (en)

Inventor

Kenneth L Arrington

Christopher Burgey

Robert Gilfillan

Yongxin Han

Mehul Patel

Chun Sing Li

Yaozong Li

Yunfu Luo

Jiayi Xu

Original Assignee

Merck Sharp & Dohme

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-10-08

Filing date

2015-03-23

Publication date

2016-06-29

2015-03-23 Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme

2016-06-29 Publication of TN2015000106A1 publication Critical patent/TN2015000106A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/56—One oxygen atom and one sulfur atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Enzymes And Modification Thereof (AREA)

TNP2015000106A 2012-10-08 2015-03-23 5-phenoxy-3h-pyrimidin-4-one derivatives and their use as hiv reverse transcriptase inhibitors TN2015000106A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
CN2012001358		2012-10-08
PCT/US2013/063612 WO2014058747A1 (fr)	2012-10-08	2013-10-07	Dérivés de 5-phénoxy-3h-pyrimidin-4-one et leur utilisation en tant qu'inhibiteurs de la transcriptase inverse du vih

Publications (1)

Publication Number	Publication Date
TN2015000106A1 true TN2015000106A1 (en)	2016-06-29

Family

ID=49354986

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP2015000106A TN2015000106A1 (en)	2012-10-08	2015-03-23	5-phenoxy-3h-pyrimidin-4-one derivatives and their use as hiv reverse transcriptase inhibitors

Country Status (46)

Country	Link
US (3)	US9469634B2 (fr)
EP (3)	EP2903977B1 (fr)
JP (2)	JP5877281B2 (fr)
KR (1)	KR101696128B1 (fr)
CN (1)	CN104822670B (fr)
AP (1)	AP2015008355A0 (fr)
AR (1)	AR092876A1 (fr)
AU (1)	AU2013329552B8 (fr)
BR (1)	BR112015007742B8 (fr)
CA (1)	CA2887312C (fr)
CL (1)	CL2015000880A1 (fr)
CO (1)	CO7350655A2 (fr)
CR (1)	CR20150183A (fr)
CY (3)	CY1119655T1 (fr)
DK (3)	DK3656384T3 (fr)
DO (1)	DOP2015000082A (fr)
EA (1)	EA033436B1 (fr)
EC (1)	ECSP15018618A (fr)
ES (3)	ES2770774T3 (fr)
GE (1)	GEP20186838B (fr)
GT (1)	GT201500088A (fr)
HR (3)	HRP20171819T1 (fr)
HU (3)	HUE037231T2 (fr)
IL (1)	IL238090B (fr)
JO (1)	JO3470B1 (fr)
LT (3)	LT3295942T (fr)
MA (1)	MA37959A2 (fr)
MD (1)	MD4625C1 (fr)
ME (1)	ME02918B (fr)
MX (1)	MX355040B (fr)
MY (1)	MY192716A (fr)
NI (1)	NI201500048A (fr)
NO (1)	NO2903977T3 (fr)
NZ (1)	NZ706729A (fr)
PE (1)	PE20151787A1 (fr)
PH (1)	PH12015500764B1 (fr)
PL (3)	PL3656384T3 (fr)
PT (3)	PT3656384T (fr)
RS (3)	RS59863B1 (fr)
SG (1)	SG11201502620UA (fr)
SI (3)	SI3656384T1 (fr)
TN (1)	TN2015000106A1 (fr)
TW (2)	TWI538907B (fr)
UA (1)	UA114006C2 (fr)
WO (1)	WO2014058747A1 (fr)
ZA (1)	ZA201503143B (fr)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20140031250A1 (en)	2010-10-07	2014-01-30	David Tsai Ting	Biomarkers of Cancer
JO3470B1 (ar)	2012-10-08	2020-07-05	Merck Sharp & Dohme	مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
US9340799B2 (en)	2013-09-06	2016-05-17	President And Fellows Of Harvard College	MRNA-sensing switchable gRNAs
US20160221965A1 (en)	2013-09-16	2016-08-04	Bayer Pharma Aktiengesellschaft	Disubstituted trifluoromethyl pyrimidinones and their use
CA2944187C (fr) *	2014-04-01	2018-06-19	Merck Sharp & Dohme Corp.	Promedicaments d'inhibiteurs de transcriptase inverse de vih
WO2015200697A1 (fr)	2014-06-25	2015-12-30	The General Hospital Corporation	Ciblage de hsatii (human satellite ii)
BR112017003745A2 (pt)	2014-08-29	2017-12-05	Tes Pharma S R L	inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico
FR3027901B1 (fr) *	2014-10-31	2018-03-16	Universite De Reims Champagne Ardenne	Nouveaux procedes appartenant a la famille des pyridazinones.
US10350165B2 (en) *	2014-12-12	2019-07-16	Ojai Energetics Pbc	Methods and systems for forming stable droplets
US12043852B2 (en)	2015-10-23	2024-07-23	President And Fellows Of Harvard College	Evolved Cas9 proteins for gene editing
KR20250103795A (ko)	2016-08-03	2025-07-07	프레지던트 앤드 펠로우즈 오브 하바드 칼리지	아데노신 핵염기 편집제 및 그의 용도
CN109804066A (zh)	2016-08-09	2019-05-24	哈佛大学的校长及成员们	可编程cas9-重组酶融合蛋白及其用途
US11542509B2 (en)	2016-08-24	2023-01-03	President And Fellows Of Harvard College	Incorporation of unnatural amino acids into proteins using base editing
AU2017342543B2 (en)	2016-10-14	2024-06-27	President And Fellows Of Harvard College	AAV delivery of nucleobase editors
WO2018119359A1 (fr)	2016-12-23	2018-06-28	President And Fellows Of Harvard College	Édition du gène récepteur ccr5 pour protéger contre l'infection par le vih
EP3592381A1 (fr)	2017-03-09	2020-01-15	President and Fellows of Harvard College	Vaccin contre le cancer
EP3592853A1 (fr)	2017-03-09	2020-01-15	President and Fellows of Harvard College	Suppression de la douleur par édition de gène
KR20190127797A (ko)	2017-03-10	2019-11-13	프레지던트 앤드 펠로우즈 오브 하바드 칼리지	시토신에서 구아닌으로의 염기 편집제
CA3057192A1 (fr)	2017-03-23	2018-09-27	President And Fellows Of Harvard College	Editeurs de nucleobase comprenant des proteines de liaison a l'adn programmable par acides nucleiques
WO2018209320A1 (fr)	2017-05-12	2018-11-15	President And Fellows Of Harvard College	Arn guides incorporés par aptazyme pour une utilisation avec crispr-cas9 dans l'édition du génome et l'activation transcriptionnelle
CN111801345A (zh)	2017-07-28	2020-10-20	哈佛大学的校长及成员们	使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
WO2019139645A2 (fr)	2017-08-30	2019-07-18	President And Fellows Of Harvard College	Éditeurs de bases à haut rendement comprenant une gam
AU2018334290A1 (en)	2017-09-18	2020-04-02	Goldfinch Bio, Inc.	Pyridazinones and methods of use thereof
CA3082251A1 (fr)	2017-10-16	2019-04-25	The Broad Institute, Inc.	Utilisations d'editeurs de bases adenosine
EP3724214A4 (fr)	2017-12-15	2021-09-01	The Broad Institute Inc.	Systèmes et procédés de prédiction des résultats de la réparation en ingénierie génétique
JP2021512956A (ja)	2018-02-06	2021-05-20	ザジェネラルホスピタルコーポレイション	腫瘍免疫応答のバイオマーカーとしてのリピートｒｎａ
HUE062096T2 (hu)	2018-04-30	2023-09-28	Ribon Therapeutics Inc	Piridazinonok PARP7-inhibitorokként
WO2019226953A1 (fr)	2018-05-23	2019-11-28	The Broad Institute, Inc.	Éditeurs de bases et leurs utilisations
EP3852533B8 (fr)	2018-09-18	2024-07-17	Gfb (Abc), Llc	Pyridazinones et leurs procédés d'utilisation
US12281338B2 (en)	2018-10-29	2025-04-22	The Broad Institute, Inc.	Nucleobase editors comprising GeoCas9 and uses thereof
EA202191711A1 (ru) *	2018-12-18	2021-10-04	Мерк Шарп И Доум Корп.	Производные пиримидона в качестве селективных цитотоксических агентов против вич-инфицированных клеток
US12351837B2 (en)	2019-01-23	2025-07-08	The Broad Institute, Inc.	Supernegatively charged proteins and uses thereof
DE112020001306T5 (de)	2019-03-19	2022-01-27	Massachusetts Institute Of Technology	Verfahren und zusammensetzungen zur editierung von nukleotidsequenzen
US12473543B2 (en)	2019-04-17	2025-11-18	The Broad Institute, Inc.	Adenine base editors with reduced off-target effects
US12371421B2 (en)	2019-04-29	2025-07-29	Ribon Therapeutics, Inc.	Solid forms of a PARP7 inhibitor
CN114026081B (zh) *	2019-05-22	2025-02-11	默沙东有限责任公司	作为针对hiv感染的细胞的选择性细胞毒性剂的吡啶酮衍生物
CN114258398A (zh)	2019-06-13	2022-03-29	总医院公司	工程化的人内源性病毒样颗粒及使用其递送至细胞的方法
EP4037680A4 (fr) *	2019-10-04	2023-10-04	Goldfinch Bio, Inc.	Traitement à base de biomarqueurs de la glomérulosclérose segmentaire focale et de la néphropathie diabétique
US12435330B2 (en)	2019-10-10	2025-10-07	The Broad Institute, Inc.	Methods and compositions for prime editing RNA
WO2021087025A1 (fr)	2019-10-30	2021-05-06	Ribon Therapeutics, Inc.	Pyridazinones utilisées en tant qu'inhibiteurs de parp7
EP4066839A4 (fr)	2019-11-28	2023-12-27	Shionogi & Co., Ltd	Agent pharmaceutique prophylactique et thérapeutique pour maladies infectieuses à vih, caractérisé en ce qu'il comprend une combinaison d'un inhibiteur d'intégrase et d'un agent anti-vih
TW202146416A (zh)	2019-12-11	2021-12-16	德商拜耳廠股份有限公司	吡唑并三𠯤
JP2023525304A (ja)	2020-05-08	2023-06-15	ザブロードインスティテュート，インコーポレーテッド	標的二本鎖ヌクレオチド配列の両鎖同時編集のための方法および組成物
BR112023001272A2 (pt)	2020-07-24	2023-04-04	Massachusetts Gen Hospital	Partículas semelhantes a vírus aprimoradas e métodos de uso das mesmas para entrega às células
CA3193099A1 (fr)	2020-09-24	2022-03-31	David R. Liu	Arn guides d'edition primaire, leurs compositions et leurs methodes d'utilisation
CA3203876A1 (fr)	2021-01-11	2022-07-14	David R. Liu	Variants d'editeur primaire, constructions et procedes pour ameliorer l'efficacite et la precision d'une edition primaire
WO2023275230A1 (fr) *	2021-07-01	2023-01-05	Janssen Pharmaceutica Nv	Acétamides 5-oxo-pyrido[2,3-d]pyridazin-6(5h)-yl
WO2023015309A2 (fr)	2021-08-06	2023-02-09	The Broad Institute, Inc.	Éditeurs primaires améliorés et leurs procédés d'utilisation
US20240417719A1 (en)	2021-10-25	2024-12-19	The Broad Institute, Inc.	Methods and compositions for editing a genome with prime editing and a recombinase
IL313146A (en)	2021-12-03	2024-07-01	Harvard College	Self-assembling virus-like particles for delivery of prime editors and methods of making and using same
WO2023205687A1 (fr)	2022-04-20	2023-10-26	The Broad Institute, Inc.	Procédés et compositions d'édition primaire améliorés
WO2023240137A1 (fr)	2022-06-08	2023-12-14	The Board Institute, Inc.	Variants de cas14a1 évolués, compositions et méthodes de fabrication et d'utilisation de ceux-ci dans l'édition génomique
WO2024077267A1 (fr)	2022-10-07	2024-04-11	The Broad Institute, Inc.	Méthodes et compositions d'édition d'amorce pour traiter des troubles de répétition de triplet
EP4619515A1 (fr)	2022-11-17	2025-09-24	The Broad Institute, Inc.	Distribution d'éditeur primaire par vaa
EP4662306A2 (fr)	2023-02-09	2025-12-17	The Broad Institute Inc.	Recombinases évoluées pour éditer un génome en combinaison avec une édition primaire
WO2024206125A1 (fr)	2023-03-24	2024-10-03	The Broad Institute, Inc.	Utilisation de l'édition primaire pour le traitement de la drépanocytose
WO2025014788A1 (fr)	2023-07-07	2025-01-16	Merck Sharp & Dohme Llc	Dérivés de tétrahydroquinazoline utilisés comme agents cytotoxiques sélectifs
WO2025081042A1 (fr)	2023-10-12	2025-04-17	Renagade Therapeutics Management Inc.	Système d'édition de précision basé sur un modèle de nickase-rétron et méthodes d'utilisation

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5663169A (en)	1992-08-07	1997-09-02	Merck & Co., Inc.	Benzoxazinones as inhibitors of HIV reverse transcriptase
CN1303378A (zh)	1998-04-27	2001-07-11	国家科研中心	3－(氨基－或氨基烷基)吡啶酮衍生物和它们在hiv相关疾病治疗中的用途
IT1305313B1 (it)	1998-07-17	2001-05-04	Colla Paolo	3,4 - diidro- 6- benzil-4-oxopirimidine sostituite e relativo processodi produzione e impiego nella terapia delle infezioni da hiv-1.
SE9904045D0 (sv)	1999-11-09	1999-11-09	Astra Ab	Compounds
AU2001296871A1 (en)	2000-09-15	2002-03-26	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
EA011164B1 (ru)	2003-02-07	2009-02-27	Янссен Фармацевтика Н. В.	Производные пиримидина для профилактики вич-инфекции
TW200423930A (en)	2003-02-18	2004-11-16	Hoffmann La Roche	Non-nucleoside reverse transcriptase inhibitors
TW200505441A (en)	2003-03-24	2005-02-16	Hoffmann La Roche	Non-nucleoside reverse transcriptase inhibitorsⅠ
CA2518823A1 (fr)	2003-03-24	2004-10-07	F.Hoffmann-La Roche Ag	Benzyl-pyridazinones en tant qu'inhibiteurs de transcriptase inverse
KR20060124701A (ko)	2004-01-12	2006-12-05	길리애드 사이언시즈, 인코포레이티드	피리미딜 포스포네이트 항바이러스성 화합물 및 그의 사용방법
CA2559552A1 (fr)	2004-03-23	2005-09-29	F. Hoffmann-La Roche Ag	Derives benzyl-pyridazinone servant d'inhibiteurs d'une transcriptase inverse non nucleosidique
ES2333802T3 (es)	2004-04-23	2010-03-01	F. Hoffmann-La Roche Ag	Inhibidores no nucleicos de transcriptasa inversa.
US7166738B2 (en)	2004-04-23	2007-01-23	Roche Palo Alto Llc	Non-nucleoside reverse transcriptase inhibitors
JP2008525419A (ja)	2004-12-22	2008-07-17	ファイザー・リミテッド	Ｈｉｖ−１逆転写酵素の非ヌクレオシド阻害剤
AR057455A1 (es)	2005-07-22	2007-12-05	Merck & Co Inc	Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
JP2009515826A (ja)	2005-10-19	2009-04-16	エフ．ホフマン−ラロシュアーゲー	フェニル−アセトアミドｎｎｒｔ阻害剤
EP1940782B1 (fr)	2005-10-19	2009-03-11	F.Hoffmann-La Roche Ag	N-phénylphénylacétamides en tant qu'inhibiteurs de transcriptases inverses non-nucléosides
WO2008062905A2 (fr)	2006-11-24	2008-05-29	Takeda Pharmaceutical Company Limited	Composé hétéromonocyclique et ses utilisations
US7803940B2 (en)	2006-11-24	2010-09-28	Takeda Pharmaceutical Company Limited	Heteromonocyclic compound or a salt thereof having strong antihypertensive action, insulin sensitizing activity and the like production thereof and use thereof for prophylaxis or treatment of cardiovascular diseases, metabolic diseases and/or central nervous system diseases
TW200831085A (en)	2006-12-13	2008-08-01	Merck & Co Inc	Non-nucleoside reverse transcriptase inhibitors
EP2222661B1 (fr) *	2007-11-20	2016-04-20	Merck Sharp & Dohme Corp.	Inhibiteurs non-nucléosidiques de la transcriptase inverse
CN103254138A (zh) *	2008-01-08	2013-08-21	默沙东公司	用于制备n-取代的羟基嘧啶酮羧酰胺类化合物的方法
PT2924034T (pt) *	2010-03-30	2017-01-06	Merck Canada Inc	Composição farmacêutica compreendendo um inibidor de transcritase reversa não nucleosídico
EP2558093A4 (fr)	2010-04-08	2013-10-02	Merck Sharp & Dohme	Promédicaments d'un inhibiteur de la transcriptase inverse du vih
JO3470B1 (ar)	2012-10-08	2020-07-05	Merck Sharp & Dohme	مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
CA2944187C (fr)	2014-04-01	2018-06-19	Merck Sharp & Dohme Corp.	Promedicaments d'inhibiteurs de transcriptase inverse de vih

2013
- 2013-09-29 JO JOP/2013/0284A patent/JO3470B1/ar active
- 2013-10-02 AR ARP130103568A patent/AR092876A1/es active IP Right Grant
- 2013-10-07 MY MYPI2015000836A patent/MY192716A/en unknown
- 2013-10-07 EA EA201590674A patent/EA033436B1/ru not_active IP Right Cessation
- 2013-10-07 SG SG11201502620UA patent/SG11201502620UA/en unknown
- 2013-10-07 WO PCT/US2013/063612 patent/WO2014058747A1/fr not_active Ceased
- 2013-10-07 ME MEP-2017-264A patent/ME02918B/fr unknown
- 2013-10-07 JP JP2015535852A patent/JP5877281B2/ja active Active
- 2013-10-07 MA MA37959A patent/MA37959A2/fr unknown
- 2013-10-07 TW TW102136225A patent/TWI538907B/zh active
- 2013-10-07 GE GEAP201313818A patent/GEP20186838B/en unknown
- 2013-10-07 PT PT192101673T patent/PT3656384T/pt unknown
- 2013-10-07 ES ES17191307T patent/ES2770774T3/es active Active
- 2013-10-07 PL PL19210167T patent/PL3656384T3/pl unknown
- 2013-10-07 AP AP2015008355A patent/AP2015008355A0/xx unknown
- 2013-10-07 TW TW105108710A patent/TWI598343B/zh active
- 2013-10-07 LT LTEP17191307.2T patent/LT3295942T/lt unknown
- 2013-10-07 PE PE2015001782A patent/PE20151787A1/es active IP Right Grant
- 2013-10-07 DK DK19210167.3T patent/DK3656384T3/da active
- 2013-10-07 RS RS20200052A patent/RS59863B1/sr unknown
- 2013-10-07 RS RS20171164A patent/RS56543B1/sr unknown
- 2013-10-07 HU HUE13776702A patent/HUE037231T2/hu unknown
- 2013-10-07 HR HRP20171819TT patent/HRP20171819T1/hr unknown
- 2013-10-07 ES ES13776702.6T patent/ES2645638T3/es active Active
- 2013-10-07 KR KR1020157011661A patent/KR101696128B1/ko active Active
- 2013-10-07 ES ES19210167T patent/ES2909190T3/es active Active
- 2013-10-07 PT PT171913072T patent/PT3295942T/pt unknown
- 2013-10-07 NZ NZ706729A patent/NZ706729A/en unknown
- 2013-10-07 LT LTEP19210167.3T patent/LT3656384T/lt unknown
- 2013-10-07 US US14/047,515 patent/US9469634B2/en active Active
- 2013-10-07 LT LTEP13776702.6T patent/LT2903977T/lt unknown
- 2013-10-07 CN CN201380061513.7A patent/CN104822670B/zh active Active
- 2013-10-07 AU AU2013329552A patent/AU2013329552B8/en active Active
- 2013-10-07 HR HRP20220502TT patent/HRP20220502T1/hr unknown
- 2013-10-07 SI SI201331974T patent/SI3656384T1/sl unknown
- 2013-10-07 EP EP13776702.6A patent/EP2903977B1/fr active Active
- 2013-10-07 CA CA2887312A patent/CA2887312C/fr active Active
- 2013-10-07 PT PT137767026T patent/PT2903977T/pt unknown
- 2013-10-07 RS RS20220359A patent/RS63112B1/sr unknown
- 2013-10-07 MD MD20150047A patent/MD4625C1/ro active IP Right Grant
- 2013-10-07 MX MX2015004448A patent/MX355040B/es active IP Right Grant
- 2013-10-07 HU HUE17191307A patent/HUE048670T2/hu unknown
- 2013-10-07 BR BR112015007742A patent/BR112015007742B8/pt active IP Right Grant
- 2013-10-07 NO NO13776702A patent/NO2903977T3/no unknown
- 2013-10-07 SI SI201330835T patent/SI2903977T1/sl unknown
- 2013-10-07 PL PL17191307T patent/PL3295942T3/pl unknown
- 2013-10-07 PL PL13776702T patent/PL2903977T3/pl unknown
- 2013-10-07 EP EP17191307.2A patent/EP3295942B1/fr active Active
- 2013-10-07 DK DK13776702.6T patent/DK2903977T3/en active
- 2013-10-07 DK DK17191307.2T patent/DK3295942T3/da active
- 2013-10-07 SI SI201331662T patent/SI3295942T1/sl unknown
- 2013-10-07 HU HUE19210167A patent/HUE058903T2/hu unknown
- 2013-10-07 UA UAA201504486A patent/UA114006C2/uk unknown
- 2013-10-07 EP EP19210167.3A patent/EP3656384B1/fr active Active
2015
- 2015-03-23 TN TNP2015000106A patent/TN2015000106A1/fr unknown
- 2015-04-01 IL IL238090A patent/IL238090B/en active IP Right Grant
- 2015-04-06 PH PH12015500764A patent/PH12015500764B1/en unknown
- 2015-04-07 NI NI201500048A patent/NI201500048A/es unknown
- 2015-04-08 GT GT201500088A patent/GT201500088A/es unknown
- 2015-04-08 CR CR20150183A patent/CR20150183A/es unknown
- 2015-04-08 DO DO2015000082A patent/DOP2015000082A/es unknown
- 2015-04-08 CO CO15077967A patent/CO7350655A2/es unknown
- 2015-04-08 CL CL2015000880A patent/CL2015000880A1/es unknown
- 2015-05-07 ZA ZA2015/03143A patent/ZA201503143B/en unknown
- 2015-05-12 EC ECIEPI201518618A patent/ECSP15018618A/es unknown
2016
- 2016-01-25 JP JP2016011415A patent/JP6097422B2/ja active Active
- 2016-02-01 US US15/012,445 patent/US9718819B2/en active Active
2017
- 2017-06-07 US US15/616,756 patent/US10189831B2/en active Active
- 2017-11-20 CY CY20171101214T patent/CY1119655T1/el unknown
2020
- 2020-01-30 HR HRP20200158TT patent/HRP20200158T1/hr unknown
- 2020-02-04 CY CY20201100097T patent/CY1122585T1/el unknown
2022
- 2022-03-30 CY CY20221100247T patent/CY1125202T1/el unknown

Also Published As

Publication number	Publication date
ECSP15018618A (es)	2019-06-30
AU2013329552B8 (en)	2017-01-12
PT2903977T (pt)	2017-11-14
TWI598343B (zh)	2017-09-11
CY1122585T1 (el)	2021-01-27
EA033436B1 (ru)	2019-10-31
ZA201503143B (en)	2016-06-29
KR20150065186A (ko)	2015-06-12
RS59863B1 (sr)	2020-03-31
SI2903977T1 (sl)	2017-12-29
CA2887312C (fr)	2017-02-28
NI201500048A (es)	2016-06-29
HRP20171819T1 (hr)	2017-12-29
PL2903977T3 (pl)	2018-01-31
DK3656384T3 (da)	2022-04-19
US20170349585A1 (en)	2017-12-07
CN104822670B (zh)	2018-01-12
US9718819B2 (en)	2017-08-01
JO3470B1 (ar)	2020-07-05
MX2015004448A (es)	2016-02-17
MX355040B (es)	2018-03-28
ES2909190T3 (es)	2022-05-05
CY1125202T1 (el)	2024-02-16
PL3656384T3 (pl)	2022-04-04
JP5877281B2 (ja)	2016-03-02
HRP20200158T1 (hr)	2020-08-07
NZ706729A (en)	2018-09-28
CR20150183A (es)	2015-08-10
ES2770774T3 (es)	2020-07-03
ME02918B (fr)	2018-10-20
SI3656384T1 (sl)	2022-05-31
KR101696128B1 (ko)	2017-01-13
TW201623256A (zh)	2016-07-01
CA2887312A1 (fr)	2014-04-17
JP2016128470A (ja)	2016-07-14
DK2903977T3 (en)	2017-12-04
ES2645638T3 (es)	2017-12-07
CL2015000880A1 (es)	2015-08-28
DK3295942T3 (da)	2020-02-10
PH12015500764B1 (en)	2019-04-05
CY1119655T1 (el)	2018-04-04
GT201500088A (es)	2017-09-28
LT3295942T (lt)	2020-02-10
SI3295942T1 (sl)	2020-03-31
PT3295942T (pt)	2020-02-18
US10189831B2 (en)	2019-01-29
HRP20220502T1 (hr)	2022-05-27
US9469634B2 (en)	2016-10-18
MD20150047A2 (ro)	2015-08-31
CO7350655A2 (es)	2015-08-10
TWI538907B (zh)	2016-06-21
HUE058903T2 (hu)	2022-09-28
WO2014058747A1 (fr)	2014-04-17
NO2903977T3 (fr)	2018-02-17
EP3656384A1 (fr)	2020-05-27
EP2903977B1 (fr)	2017-09-20
MD4625C1 (ro)	2019-11-30
RS56543B1 (sr)	2018-02-28
HUE048670T2 (hu)	2020-08-28
US20140100231A1 (en)	2014-04-10
MA37959A2 (fr)	2017-12-29
DOP2015000082A (es)	2015-08-16
AR092876A1 (es)	2015-05-06
CN104822670A (zh)	2015-08-05
BR112015007742B8 (pt)	2021-03-23
EP3295942A1 (fr)	2018-03-21
LT3656384T (lt)	2022-05-10
AP2015008355A0 (en)	2015-04-30
RS63112B1 (sr)	2022-05-31
EP2903977A1 (fr)	2015-08-12
PH12015500764A1 (en)	2015-07-27
HK1252786A1 (en)	2019-05-31
PT3656384T (pt)	2022-03-22
AU2013329552B2 (en)	2016-09-15
MD4625B1 (ro)	2019-04-30
IL238090B (en)	2019-02-28
EA201590674A1 (ru)	2016-02-29
HK1207369A1 (en)	2016-01-29
AU2013329552C1 (en)	2016-12-22
JP6097422B2 (ja)	2017-03-15
AU2013329552A1 (en)	2015-04-16
EP3295942B1 (fr)	2019-11-20
TW201420576A (zh)	2014-06-01
EP3656384B1 (fr)	2022-02-23
UA114006C2 (xx)	2017-04-10
PL3295942T3 (pl)	2020-05-18
BR112015007742A2 (pt)	2017-08-08
LT2903977T (lt)	2017-12-11
US20160145255A1 (en)	2016-05-26
JP2015533123A (ja)	2015-11-19
BR112015007742B1 (pt)	2021-01-19
GEP20186838B (en)	2018-04-10
MY192716A (en)	2022-09-05
HUE037231T2 (hu)	2018-08-28
SG11201502620UA (en)	2015-05-28
PE20151787A1 (es)	2015-12-03

Publication	Publication Date	Title
PH12015500764A1 (en)	2015-07-27	5-phenoxy-3h-pyrimidin-4-one derivatives and their use as hiv reverse transcriptase inhibitors
TN2012000455A1 (en)	2014-01-30	Non-nucleoside reverse transcriptase inhibitors
MX2019007262A (es)	2019-09-05	Compuestos antivirales de bencilamina fosfodiamida.
PH12018500292A1 (en)	2018-08-20	Antiviral beta-amino acid ester phosphodiame compounds
MX388757B (es)	2025-03-20	Profármacos de éster alifático antivíricos de tenofovir.
TN2009000243A1 (en)	2010-10-18	Non-nucleoside reverse transcriptase inhibitors
WO2008054605A3 (fr)	2008-07-31	Inhibiteurs de transcriptase inverse non nucléosidique
MX2016012915A (es)	2016-12-07	Profarmacos de inhibidores de la transcriptasa inversa del virus de la inmunodeficiencia humana (vih).
EA201170537A1 (ru)	2011-12-30	Ингибиторы вич-интегразы
WO2015017393A3 (fr)	2015-11-05	Dérivés de pipérazine utilisés en tant qu'inhibiteurs de la protéase du vih
WO2011025683A8 (fr)	2011-09-22	Inhibiteurs de l'intégrase du vih
WO2007002481A3 (fr)	2007-11-15	Inhibiteurs non nucleosidiques de la transcriptase inverse
TN2011000151A1 (en)	2012-09-05	Hiv integrase inhibitors
UA108495C2 (en)	2015-05-12	Reverse transcriptase nucleoside inhibitors
CY1116437T1 (el)	2017-02-08	Μη νουκλεοσιδικοι αναστολεις αναστροφης μεταγραφασης